Here is one of the reasons the stock is up about 60% in six weeks since the above Blog:
GAITHERSBURG, Md., March 3 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq:GNVC - News) announced the publication of new preclinical research revealing mechanisms by which TNFerade(TM) suppresses cancer metastases through activation of the immune system.You can the details at the above link. Or just look at the GNVC Daily Trend Model below:
This is another one of those lottery ticket plays, the upside of which seems virtually unlimited as they advance their science and collaborations with big phrama. It looks to me like that spike high at 3.34 at the end of January is going to be tested. If and when it get taken out, someone remind me again about that January 14th write-up.